Login / Signup

Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.

Jeffrey R CurtisHuifeng YunLang ChenStephanie S FordHubert van HoogstratenStefano FioreKerri FordAmy PraestgaardMarkus RehbergErnest H S Choy
Published in: Rheumatology and therapy (2023)
In real-world setting, sarilumab demonstrated treatment effectiveness, with greater improvements in the most selective population, mirroring phase 3 TNFi-refractory and rule-positive RA patients. Seropositivity appeared a stronger driver for treatment response than CRP, although optimization of the rule in routine practice requires further data.
Keyphrases